Background: Clinicians and researchers synthesize data from randomized controlled trials (RCTs) of antidepressants to make conclusions about the efficacy of medications for depression. All treatments include nonspecific factors in addition to the specific effects of drugs, and study design may influence patient outcomes via nonspecific factors. This study investigated whether placebo control and treatment duration affect the outcome in antidepressant RCTs. Methods: Medline and the Cochrane Database were searched to identify RCTs of antidepressants for major depression approved by the Food and Drug Administration. Included studies enrolled outpatient participants aged 18–65, lasted 6–12 weeks, compared an antidepressant to placebo or another antidepressant and were published in English after 1985. Excluded trials enrolled inpatients, pregnant women and subjects with psychosis or mania. Mixed-effects logistic regression models including study type (placebo-controlled or comparator) and study duration (6, 8 or 12 weeks) as fixed effects determined whether these factors affected response and remission rates. Results: In the 90 trials analyzed, the odds of depression response (OR = 1.79, 95% CI = 1.45–2.17, p < 0.001) and remission (OR 1.53, 95% CI = 1.11–2.11, p < 0.001) were significantly higher in comparator relative to placebo-controlled trials. Trials lasting 8 (OR = 1.37, CI = 1.14–1.64, p = 0.001) and 12 (OR = 1.52, CI = 1.12–2.07, p = 0.008) weeks had significantly greater response rates than 6-week trials without differing themselves. Conclusions: Response and remission rates to antidepressants are significantly affected by study type and duration. Clinicians and researchers must consider the study design when interpreting and designing RCTs of antidepressant medications.

Keywords:
Clinical trial, Methodology, Placebo, Comparator, Major depression, Duration, expectations
1.
Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB: Evidence-Based Medicine: How to Practice and Teach EBM. London, Churchill-Livingstone, 1997.
2.
Kim SY, Halloway RG: Burdens and benefits of placebos in antidepressant clinical trials: a decision and cost-effectiveness analysis. Am J Psychiatry 2003;160:1272–1276.
3.
Georgotas A, McCue RE: The additional benefit of extending an antidepressant trial past seven weeks in the depressed elderly. Int J Geriatr Psychiaty 1989;4:191–195.
4.
Roose SP, Schatzberg AF: The efficacy of antidepressants in the treatment of late-life depression. J Clin Psychopharmacol 2005;25(suppl 1):S1–S7.
5.
Khan A, Kolts RL, Thase ME, Krishnan RR, Brown W: Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004;161:2045–2049.
6.
Gaudiano BA, Herbert JD: Methodological issues in clinical trials of antidepressant medications: perspectives from psychotherapy outcome research. Psychother Psychosom 2005;74:17–25.
7.
Trivedi M, Rush J: Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology 1995;11:33–43.
8.
Sneed JR, Rutherford BR, Rindskopf D, Roose SP: Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry 2008;16:65–73.
9.
Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A: Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171–1180.
10.
Jiang W, Krishnan RR, O’Connor CM: Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002;16:111–127.
11.
Kennedy N, Paykel ES: Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord 2004;80:135–144.
12.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
13.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory of measuring depression. Arch Gen Psychiatry 1961;4:53–63.
14.
Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
15.
Guy W: Clinical global impressions; in: ECDEU Assessment Manual for Psychopharmacology, revised (DHEW publ No ADM 76-338). Rockville, National Institute of Mental Health, 1976, pp 218–222.
16.
Juni P, Altman DG, Egger M: Assessing the quality of randomized controlled trials; in Egger M (ed): Systematic Reviews in Health Care. Meta-Analysis in Context. New York, BMJ Publishing Group, 2001, pp 87–108.
17.
Bryk AS, Raudenbush SW: Hierarchical Linear Models. Newbury Park, Sage Publications, 1992.
18.
Hox J: Multilevel Analysis. Techniques and Applications. Mahwah, Erlbaum Publishers, 2002.
19.
Haddock CK, Rindskopf D, Shadish WR: Using odds ratios as effect sizes for meta-analysis of dichotomous data: a primer on methods and issues. Psychol Methods 1998;3:339–353.
20.
Amsterdam JD: A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003;64:208–214.
21.
Bodkin JA, Amsterdam JD: Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002;159:1869–1875.
22.
Burke WJ, Gergel I, Bose A: Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331–336.
23.
Byerley WF, Reimherr FW, Wood DR, Grosser BL: Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988;8:112–115.
24.
Claghorn JL, Earl CQ, Walczak DD, Stoner KA, Wong LF, Kanter D, Houser V: Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996;16:113–120.
25.
Claghorn JL, Kiev A, Rickles K, Smith WT, Dunbar GC: Paroxetine versus placebo: a double-blind comparison in depressed patients. J Clin Psychiatry 1992;53:434–438.
26.
Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O’Brien K, Ieni JR: Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996;57(suppl 2):15–18.
27.
Cohn JB, Wilcox C: A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985;46:26–31.
28.
Coleman CC, Cunningham LA, Foster VJ, Batey SR, Donahue RM, Houser TL, Ascher JA: Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11:205–215.
29.
Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, Ascher J, Batey S, Jamerson B, Metz A: A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001;23:1040–1058.
30.
Croft H, Settle E, Houser T, Batey SR, Donahue MJ, Ascher JA: A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21:643–658.
31.
Cunningham LA, Venlafaxine XR 208 Study Group: Once-daily venlafaxine extended release XR and venlafaxine immediate release IR in outpatients with major depression. Ann Clin Psychiatry 1997;9:157–164.
32.
Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E: A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99–106.
33.
Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308–315.
34.
Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383–390.
35.
Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457–470.
36.
Dunbar GC, Claghorn JL, Kiev A, Rickels K, Smith WT: A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand 1993;87:302–305.
37.
Dunlop SR, Dornseif BE, Wernicke JF, Potvin JH: Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull 1990;26:173–180.
38.
Fabre LF: A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry 1992;53(suppl):40–43.
39.
Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL: A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998;10:145–150.
40.
Feighner JP, Cohn JB, Fabre LF Jr, Fieve RR, Mendels J, Shrivastava RK, Dunbar GC: A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord 1993;28:71–79.
41.
Feighner JP, Overo K: Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 1999;60:824–830.
42.
Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, Ecker JA, Faludi G: A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234–241.
43.
Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dubé EM: Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002;63:577–584.
44.
Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA: Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389–399.
45.
Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225–231.
46.
Khan A, Upton GV, Venlafaxine Investigator Study Group: The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998;18:19–25.
47.
Lepola UM, Loft H, Reines EH: Escitalopram 10–20 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211–217.
48.
Lineberry CG, Johnston JA, Raymond RN, Samara B, Feighner JP, Harto NE, Granacher RP Jr, Weisler RH, Carman JS, Boyer WF: A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 1990;51:194–199.
49.
Lydiard RB, Laird LK, Morton WA Jr, Steele TE, Kellner C, Laraia MT, Ballenger JC: Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull 1989;25:68–70.
50.
Lydiard RB, Stahl SM, Hertzman M, Harrison WM: A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997;58:484–491.
51.
Mendels J, Johnston R, Mattes J, Riesenberg R: Efficacy and safety of bid doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;29:169–174.
52.
Peselow E, Filippi AM, Goodnick P: The short- and long-term efficacy of paroxetine HCl: data from a 6-week double-blind parallel design trial vs imipramine and placebo. Psychopharmacol Bull 1989;25:267–271.
53.
Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels J: Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51(suppl B):18–27.
54.
Rickels K, Schweizer E, Clary C, Fox I, Weise C: Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiary 1994;164:802–805.
55.
Roth D, Mattes J, Sheehan KH, Sheehan DV: A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:929–939.
56.
Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT: A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116–122.
57.
Rudolph RL, Feiger AD: A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release XR and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171–181.
58.
Schweizer E, Feighner J, Mandos K, Rickels K: Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104–108.
59.
Shrivastava RK, Shrivastava SH, Overweg N, Blumhardt CL: A double-blind comparison of paroxetine, imipramine, and placebo in major depression. J Clin Psychiatry 1992;53(suppl):48–51.
60.
Smith WT, Glaudin V: A placebo-controlled trial of paroxetine in the treatment of major depression. J Clin Psychiatry 1992;53 (suppl):36–39.
61.
Smith WT, Glaudin V, Panagides J, Gilvary E: Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191–196.
62.
Thase ME, Venlafaxine XR 209 Study Group: Efficacy and tolerability of once-daily venlafaxine extended release XR in outpatients with major depression. J Clin Psychiatry 1997;58:393–398.
63.
Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD: Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1356–1364.
64.
Wade A, Lemming OM, Bang Hedegaard K: Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95–102.
65.
Walczak DD, Apter JT, Halikas JA, Borison RL, Carman JS, Post GL, Patrick R, Cohn JB, Cunningham LA, Rittberg B, Preskorn SH, Kang JS, Wilcox CS: The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 1996;8:139–151.
66.
Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M: Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24:183–188.
67.
Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL: Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23:164–168.
68.
Alves C, Cachola I, Brandao J: Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Psychiatry 1999;5:57–63.
69.
Baldwin DS, Hawley CJ: A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996;57(suppl 2):46–52.
70.
Beasley CM, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME: Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991;52:294–299.
71.
Behnke K, Sogaard J, Martin S, Bäuml J, Ravindran AV, Agren H, Vester-Blokland ED: Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003;23:358–364.
72.
Benkert O, Szegedi A, Kohnen R: Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61:656–663.
73.
Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190–1196.
74.
Bignamini A, Rapisarda V, Italian Paroxetine Study Group: A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Int Clin Psychopharmacol 1992;6(suppl 4):37–41.
75.
Bouchard JM, Delaunay J, Delisle JP, Grasset N, Mermberg PF, Molczadzki M, Pagot R, Richou H, Robert G, Ropert R: Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients. Acta Psychiatr Scand 1987;76:583–592.
76.
Chouinard G, Saxena B, Bélanger MC, Ravindran A, Bakish D, Beauclair L, Morris P, Vasavan Nair NP, Manchanda R, Reesal R, Remick R, O’Neill MC: A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 1999;54:39–48.
77.
Christiansen PE, Behnke K, Black CH, Öhrström JK, Bork-Rasmussen H, Nilsson J: Paroxetine and amitriptyline in the treatment of depression in general practice. Acta Psychiatr Scand 1996;93:158–163.
78.
Costa e Silva J: Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998;59:352–357.
79.
Dalery J, Honig A: Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison. Hum Psychopharmacol 2003;18:379–384.
80.
Davey A: A comparison of two oral dosage regimens of 150 mg trazodone in the treatment of depression in general practice. Psychopharmacology 1988;95(suppl):S25–S30.
81.
De Wilde J, Spiers R, Mertens C, Bartholomé F, Schotte G, Leyman S: A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993;87:141–145.
82.
Debus JR, Rush AJ, Himmel C, Tyler D, Polatin P: Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry 1988;49:422–426.
83.
Dierick M, Ravizza L, Realini R, Martin A: A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiary 1996;20:57–71.
84.
Fawcett J: Fluoxetine versus amitriptyline in adult outpatients with major depression. Curr Ther Res 1989;45:821–832.
85.
Feiger A, Kiev A, Shrivastava RK, Wisselink PG: Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57(suppl 2):53–62.
86.
Feighner JP, Gardener EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, Lineberry CG: Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991;52:329–335.
87.
Fournier J: A double-blind comparison of sertraline and imipramine in outpatients with major depression: acute 8 weeks and continuation 16 weeks treatment. Hum Psychopharmacol 1997;12:203–215.
88.
Gentil V, Kerr-Correa F, Moreno R: Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol 2000;14:61–66.
89.
Hicks JA, Argyropoulos SV, Rich AS, Nash JR, Bell CJ, Edwards C, Nutt DJ, Wilson SJ: Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiary 2002;180:528–535.
90.
Hong CJ, Hu WH, Chen CC, Hsiao CC, Tsai SJ, Ruwe FJ: A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks’ treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003;64:921–926.
91.
Kasper S, Olivieri L, Di Loreto G, Dionisio P: A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin 2005;21:1139–1146.
92.
Keegan D, Bowen RC, Blackshaw S, Saleh S, Dayal N: A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int Clin Psychopharmacol 1991;6:117–124.
93.
Leinonen E, Skarstein J, Nordic Antidepressant Study Group: Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 1999;14:329–337.
94.
McPartlin G, Reynolds A, Anderson C: A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry 1998;693:127–132.
95.
Mehtonen OP, Sogaard J Venlafaxine 631 Study Group: Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 2000;61:95–100.
96.
Moller HJ, Glaser K, Leverkus F, Goebel C: Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression. Pharmacopsychiatry 2000;33:206–212.
97.
Montgomery SA, Huusom AK, Bothmer J: A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57–64.
98.
Moore N, Verdoux H, Fantino B: Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131–137.
99.
Noguera R, Altuna R, Alvarez E, Ayuso JL, Casais L, Udina C: Fluoxetine vs clomipramine in depressed patients: a controlled multicentre trial. J Affect Disord 1991;22:119–124.
100.
Ohrberg S, Christiansen PE, Severin B, Calberg H, Nilakantan B, Borup A, Søgaard J, Larsen SB, Loldrup D, Bahr B: Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatr Scand 1992;86:437–444.
101.
Ontiveros A: A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression. Br J Clin Res 1997;8:23–32.
102.
Patris M, Bouchard JM, Bougerol T, Charbonnier JF, Chevalier JF, Clerc G, Cyran C, Van Amerongen P, Lemming O, Høpfner Petersen HE: Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129–136.
103.
Perry PJ, Garvey MJ, Kelly MW, Cook BL, Dunner FJ, Winokur G: A comparative trial of fluoxetine versus trazodone in outpatients with major depression. J Clin Psychiatry 1989;50:290–294.
104.
Rickels K, Smith WT, Glaudin V, Amsterdam JB, Weise C, Settle GP: Comparison of two dosage regimens of fluoxetine in major depression. J Clin Psychiatry 1985;46:38–41.
105.
Samuelian JC, Hackett D: A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression. J Psychopharmacol 1998;12:273–278.
106.
Sauer H, Huppertz-Helmhold S, Dierkes W: Efficacy and safety of venlafaxine ER vs amitriptyline ER in patients with major depression of moderate severity. Pharmacopsychiatry 2003;36:169–175.
107.
Swann AC, Bowden CL, Rush AJ, Rhoades H, Rose R, Kobes R: Desipramine versus phenelzine in recurrent unipolar depression: clinical characteristics and treatment response. J Clin Psychopharmacol 1997;17:78–83.
108.
Tylee A, Beaumont G, Bowden MW: A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Prim Care Psychiatry 1997;3:51–58.
109.
Weisler RH, Johnston JA, Lineberry CG, Samara B, Branconnier RJ, Billow AA: Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994;14:170–179.
110.
Lohr JM, DeMaio C, McGlynn FD: Specific and nonspecific treatment factors in the experimental analysis of behavioral treatment efficacy. Behav Modif 2003;27:322–368.
111.
Vieta E, Carne X: The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom 2005;74:10–16.
112.
Noble LM, Douglas BC, Newman SP: What do patients expect of psychiatric services? A systematic and critical review of empirical studies. Soc Sci Med 2001;52:985–998.
113.
Sotsky AM, Glass DR, Shea MT, Pilkonis PA, Collins F, Elkin I, Watkins JT, Imber SD, Leber WR, Moyer J, Oliveri ME: Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 1991;148:997–1008.
114.
Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M: Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psychiatry 2004;65:1174–1179.
115.
Haour F: Mechanisms of the placebo effect and of conditioning. Neuroimmunomodulation 2005;12:195–200.
116.
Kirsch I: Specifying nonspecifics: psychological mechanisms of placebo effects; in Harrington A (ed): The Placebo Effect. An Interdisciplinary Exploration. Cambridge, Harvard University Press, 1997.
117.
Walsh BT, Seidman SN, Sysko R, Gould M: Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840–1847.
118.
Kirsch I, Deacon BJ, Huedo-Medina TB, Scorboria A, Moore TJ, Johnson BT: Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:260–268.
119.
Mojtabai R: Increase in antidepressant medication in the US adult population between 1990 and 2003. Psychother Psychosom 2008;77:83–92.
120.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905–1917.
121.
Bockting CLH, ten Doesschate MC, Spijker J, Spinhoven P, Koeter MWJ, Schene AH, DELTA Study Group: Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom 2008;77:17–26.
122.
Khan A, Leventhal R, Khan S, Brown WA: Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration Database. J Clin Psychopharmacol 2002;22:40–45.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.